Skip to main content
. Author manuscript; available in PMC: 2020 Nov 14.
Published in final edited form as: J Med Chem. 2019 Oct 21;62(21):9471–9487. doi: 10.1021/acs.jmedchem.9b00846

Figure 5. The cellular activity of MG-277 is dependent on cereblon binding.

Figure 5.

(A-D) Cell growth inhibitory activity of MI-2103, MD-222 and MG-277 in RS4;11, RS4;11/IRMI-2, MDA-MB-231 and MDA-MB-468 cells in the presence or absence of excess lenalidomide to occupy the binding site on cereblon. (E-H) Cell growth inhibitory activity of MI-2103, MG-277 and MC-024 with no cereblon binding in RS4;11, RS4;11/IRMI-2, MDA-MB-231 and MDA-MB-468 cell lines by a 4-day cell viability assay. (I) Structure of MC-024 with the amino group of the glutarimide in MG-277 methylated.